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http://dx.doi.org/10.1016/j.stemcr.2017.02.018SUMMARYAge-related skeletal degeneration in patients with osteoporosis is characterized by decreased bone mass and occurs concomitant with an
increase in bonemarrow adipocytes. Usingmicroarray expression profiling with high temporal resolution, we identified gene regulatory
events in early stages of osteogenic and adipogenic lineage commitment of human mesenchymal stromal cells (hMSCs). Data analysis
revealed three distinct phases when cells adopt a committed expression phenotype: initiation of differentiation (0–3 hr, phase I), lineage
acquisition (6–24 hr, phase II), and early lineage progression (48–96 hr, phase III). Upstream regulator analysis identified 34 transcription
factors (TFs) in phase I with a role in hMSC differentiation. Interestingly, expression levels of identified TFs did not always change and
indicate additional post-transcriptional regulatory mechanisms. Functional analysis revealed that forced expression of IRF2 enhances
osteogenic differentiation. Thus, IRF2 and other early-responder TFs may control osteogenic cell fate of MSCs and should be considered
in mechanistic models that clarify bone-anabolic changes during clinical progression of osteoporosis.INTRODUCTION
Mesenchymal stem/stromal cells (MSCs) are an excellent
biological source for bone regenerative therapies, tissue en-
gineering, and treatment of post-menopausal osteoporosis
(Murphy et al., 2013; Steinert et al., 2012). Ex vivo expan-
sion of autologous bone marrow stromal cells and system-
atic administration of hMSCs was proposed 20 years ago to
treat patients with osteoporosis (Bruder et al., 1997). To
date, treatment of osteoporosis using bonemarrow-derived
MSCs is not yet standard clinical practice. Donor variation
among patients and unpredictable capacity for differentia-
tion are among the current shortcomings of hMSCs for
their application in regenerative cell therapies (Murphy
et al., 2013).
In MSCs, transcription factors (TFs) such as RUNX2,
SP7/Osterix, and SOX9 have been shown to play critical
roles in differentiation of MSCs into osteoblasts or
chondrocytes. Overexpression of RUNX2 in non-osteo-
blastic cells or in adipose-tissue-derived MSCs increases
expression of osteoblastic markers and enhances osteo-
blast differentiation and mineralization (Ducy et al.,
1997; Otto et al., 1997; Zhang et al., 2006). Moreover,
homozygous RUNX2 mutant mice lack mature osteo-
blasts and mineralized bone, indicating that a single
TF is important for bone development and osteoblast
differentiation.Stem Ce
This is an open access article under the CBesides differentiation into osteoblasts, MSCs can differ-
entiate into other cell lineages such as adipocytes and
chondrocytes (Pittenger et al., 1999). The identification
of regulators of lineage commitment is therefore an essen-
tial step toward our understanding and control of human
MSC differentiation into osteoblasts. The balance between
osteoblast and adipocyte differentiation is of specific inter-
est. Increased adipose tissue volume is observed in the bone
marrow cavity in osteoporotic people where increased
bone resorption is not sufficiently compensated by an in-
crease in bone formation by osteoblasts (Justesen et al.,
2001; Yeung et al., 2005). The hypothesis underlying the
current study is that detailed analysis of gene expression
changes upon induction of osteogenic and adipogenic dif-
ferentiation of MSCs enables identification of TFs that
change activity during early differentiation in both line-
ages. While previous gene expression studies identified
important regulatory pathways and processes involved in
MSC differentiation, the results are limited by differentia-
tion into a single mesenchymal lineage, a later stage of dif-
ferentiation, and/or a low temporal density at early time
points (Hung et al., 2004; Kulterer et al., 2007; Ng et al.,
2008; Piek et al., 2010). Because key lineage decisions are
made during the early stages of mesenchymal differentia-
tion, a high density of early time points of differentiation
is critical for the identification of important regulators
within the initial differentiation phases.ll Reports j Vol. 8 j 947–960 j April 11, 2017 j ª 2017 The Author(s). 947
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Dynamic Transcriptional Changes upon Adipogenic and Osteogenic Differentiation of hMSCs
(A) Histochemical staining of calcium with Alizarin red (ARS) or adipocyte with oil red O (ORO) after 25 days of osteogenic (OS) or
adipogenic (AD) differentiation. Scale bars, 200 mm.
(B) Biochemical analyses of osteogenic differentiating human mesenchymal stromal cells that were used to generated the gene expression
profiles. Error bars indicate SD. Mean and SD of two independent experiments with two technical replicates.
(legend continued on next page)
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Here, we systematically investigated gene expression
changes upon differentiation of human MSCs into adipo-
cytes and osteoblasts with high temporal resolution. One
of our key findings was the identification of three distinct
sequential phases of differentiation in both lineages.
Furthermore, we characterized genes and regulatory pro-
grams controlling the early stages of mesenchymal lineage
commitment. These findings provide opportunities for de-
signed engineering of hMSCs for applications in both
personalized and regenerative medicine.RESULTS
Differentiation of hMSCs into Osteoblasts and
Adipocytes
To analyze dynamic transcriptional networks in early
differentiating human MSCs (hMSCs), we generated gene
expression profiles with a high temporal density during
the first 4 days of osteogenic and adipogenic differentia-
tion. Histological staining for calcium and lipids in osteo-
genic and adipogenic differentiation cultures show that,
respectively, the extracellular matrix (ECM) is mineralized
and cells accumulate intracellular lipid vesicles as shown
at day 25 (Figure 1A). Biochemical analyses of samples
during differentiation show that total protein and alkaline
phosphatase (ALP) activity transiently increases during
osteogenic differentiation prior to a decrease of ALP
upon mineralization (Figure 1B). ALP activity is similarly
increased during adipogenic differentiation (Figure 1B).
ECMmineralization is observed after 21 days of osteogenic
differentiation as demonstrated by increased calciumdepo-
sition in the matrix (Figures 1A and 1B). Together, our
observations establish that hMSCs differentiate into both
lineages, consistent with their expected multi-lineage
potential.
Analysis of gene expression dynamics during hMSC dif-
ferentiation reveals that transcript levels immediately
change upon induction of differentiation (Figure 1C). To
gain insight into the robustness of the gene expression
changes, we selected genes that were specifically upregu-
lated during osteogenic or adipogenic differentiation. We
validated their change in expression inMSCs from an addi-
tional donor as well as during osteogenic differentiation of
a committed human osteoblast cell line (NHOst). These an-(C) Number of significant differential probes (q < 0.001) relative to un
with 10–20 technical replicated measurements in a single donor).
(D) Number of significant differential probes (q < 0.001) relative to th
was divided by the time differences between two time points (based
(E) Principle component analyses of the osteogenic (1), adipogenic (2)
probes that were detected as expressed. Replicated (based on the same
time point (blue, osteogenic; red, adipogenic). Gray circles indicatealyses supported the observations obtained by themicroar-
ray gene expression analysis (Figure S1A). During induc-
tion of osteogenic differentiation, at least 44 gene probes
are significantly different at 30 min and this increases
further to 351 after 2 hr. The number of significantlymodu-
lated probes gradually increases and begins to level off after
2 days with a maximum number of 3,178 probes after
3 days of osteogenic differentiation. Comparable results
were obtained during adipogenic differentiation where
the number of differentially expressed probes was 46 after
30 min, 470 after 2 hr, and 3,863 by day 3. Remarkably,
within the first 2 hr of differentiation, most of the genes
that are modulated are upregulated (276 of 351 probes
for osteogenic and 301 of 470 probes for adipogenic
induction) (Figures S1B and S1C). Yet, the number of
up- and downregulated genes is about the same in the
two subsequent phases. These results suggest that tran-
scription exceeds median mRNA degradation during the
initial induction of differentiation. Gene expression at later
stages of differentiation may be controlled by transcrip-
tional repression combined with non-specific mRNA decay
and/or constitutive transcription with enhanced mRNA
destabilization.
Next, we calculated the number of significant differen-
tially expressed probes at each time point compared with
the preceding time point and divided the differences by
the elapsed time (Figure 1D, right panel). Adipogenic differ-
entiating cells showed a similar number of differentially
expressed probes during the first 2 hr, but thereafter the
number of gene expression changes per hour was almost
two times higher than in the osteogenic differentiation
cells and is in agreement with recent studies suggesting
the default preference of bone marrow-derived MSCs for
osteogenic differentiation (Meyer et al., 2016). In both con-
ditions, the number of probes that changed per hour
decreased drastically after 48 hr of differentiation, and
onlyminor gene expression changes were evident between
days 2 and 4 (Figure 1D).
More than 20% of genes change expression in the early
phase (first 3 hr) of osteogenic differentiation (Figure 1C).
We assessed whether this dramatic change is mostly due
to uncoordinated gene activation and repression or pro-
ceeds in a more organized and sequential manner that
reflects a well-defined single differentiation program in
which the number of modulated mRNAs per time perioddifferentiated cells (t = 0) (based on three independent experiment
e previous time point. The number of differential expressed probes
on the same replicated samples as in C).
, and all (3) gene expression profiling experiments using the 15,795
replicated samples as in C) probe intensities were averaged for each
differentiation phases as described in the text.
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Figure 2. Functional Annotation of Differential Expressed Genes
(A) Heatmap of differentially regulated probes compared with undifferentiated cells (t = 0 hr) Replicated (based on the same replicated
samples as in Figure 1C) probe intensities were averaged for each time point.
(B) Analyses of enriched functional categories among the probes that were differentially expressed during adipogenic and osteogenic
differentiating hMSCs. The cluster diagram depicts thelog10(p value) of the enrichment. Only significant (p < 0.05) instances are shown.
Colors on the side of the cluster diagram depict the similarly associated functional categories.
(C) Significance of enrichment of the functional categories, TF activity and cell cycle, during differentiation.
(D) Venn diagram of the functional categories that are similarly enriched, TF activity and cell cycle, and extracellular matrix proteins, a
functional category that is enriched earlier in osteoblasts. The numbers inside the Venn diagram are the number of significantly expressed
(legend continued on next page)
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increases during early lineage commitment and progres-
sion. Principal component analysis (PCA) was applied to
examine whether expression produces a single dominant
principal component (PC), and whether there is co-line-
arity between time and progression along that component.
The PCA shows indeed a rather dominant first principal PC
that encompasses two-thirds of the variation in expression
(Figure 1E, 1 and 2). In this dimension, both lineages differ-
entiate away from the undifferentiatedMSCs. Gene expres-
sion (and its inherent variation) at a given biological time
point generates time stamps. Since these time stamps occur
in a precise order within the diagram, it appears that the
process of differentiation of both lineages resembles an or-
dered program rather than an uncoordinated set of events.
By performing a single PCA on the data of both lineages,
we addressed similarities and differences in the differentia-
tion programs of the two lineages. We found that both lin-
eages display a unique series of time stamps that occur in
sequence on a single line (Figures 1E, 3, and S1D). The
time stamp lines for the two lineages move in the direction
of the main PC and diverge steadily over time, consistent
with the early adoption of two distinct mesenchymal
phenotypes. The osteogenic and adipogenic lineages
already diverge within 2–3 hr upon induction of differenti-
ation, and three phases can be discerned in each lineage
(Figure 1E, 3).
Global gene expression analyses at high temporal resolu-
tion and unsupervised clustering of the microarray data
defines three distinct sub-stages (phase 1, 0–3 hr; phase II,
6–24 hr; phase III, 48–96 hr) and dynamic transcriptional
responses during differentiation of hMSCs into either
osteogenic or adipogenic lineages (Figure 1E). Hence,
mesenchymal differentiation into the cellular lineages
that produce mature bone or fat tissue is a multi-stage pro-
cess. Furthermore, phenotype commitment is initiated
quite rapidly following induction.
Gene Ontology Analysis Reveals General and Lineage-
Specific Functional Processes during Differentiation
To understand mechanistic cellular changes upon induc-
tion of differentiation, we used the gene expression profiles
to assess the functional categories that were significantly
enriched at the different time points after induction of
differentiation into both lineages. Differentially expressed
probes at each individual time point (Figure 2A) were sub-
jected to a gene ontology analyses, and the most signifi-
cantly enriched functional categories were visualized in a
hierarchical clustering diagram (Figure 2B and Table S1).probes at the time point indicated. The numbers of up- or downregul
oppositely regulated in the two conditions are shown below the Venn
(E) Significance of enrichment of functional categories, extracellula
during osteoblast or adipocyte differentiating hMSCs, respectively.The clustering of enriched functional categories illus-
trates that modulated genes in the first phase are highly
different from those in the second and third phases. Impor-
tantly, the gene expression program of both lineages
are enriched in similar gene ontology terms, consistent
with classical models for cellular differentiation in which
changes in cell proliferation accompany the acquisition
of lineage-committed cellular phenotypes. These func-
tional categories include transcriptional regulation (en-
riched in phase I), apoptosis (enriched in phases I and II),
as well as cell-cycle/DNA replication and mitosis (enriched
in phases II and III) (Figures 2B and 2C).
Because similar functional categories are enriched in
both lineages, for each lineage we investigatedwhich genes
are differentially expressed. Expression of 45 probes linked
to transcriptional control is modulated in both lineages
within 3 hr of differentiation (phase I), and these genes
may represent a class of common early-responder TFs in
phase I (Figure 2D). We also observed 22 and 46 TF activ-
ity-linked probes that are specifically regulated within the
initiation phase of osteogenic and adipogenic differentia-
tion (phase I), respectively. Furthermore, 53 and 99 probes
linked to cell-cyclemechanisms are differentially expressed
in the osteogenic and adipogenic lineages at 48 hr, respec-
tively, when cells progress from a lineage-acquisition phase
(phase II) into the lineage-progression phase (phase III)
(Figure 2D). The situation is clear but paradoxical: the
two lineages are largely similar in terms of functional
categories, yet distinctly; the differences between the two
lineages set in early (second PC in Figure 1E and detailed
differences of the differential expressed TFs in Figure 2D,
upper panel).
We note that many probes (n = 188) associated with the
cell cycle are differentially expressed in both lineages after
48 hr, and about 85% of these probes are downregulated
(Figure 2D). This result indicates that induction of differen-
tiation in both lineages coincides with downregulation of
the expression program that mediates orderly progression
through the mitotic cell cycle. More importantly, the
modulated expression of 185 common probes may define
a shared mesenchymal cell-cycle program of downregu-
lated cell-cycle stimulatory factors (CCNA2, CCNB1,
CCNB2, CCND1, CCNE1, CCNE2, and CCNF; and E2Fs:
E2F2 and E2F7) and upregulated cell-cycle inhibitors
(CDKN1C and CDKN2C) that is coordinately controlled
in each lineage.
Besides functional categories that were enriched in both
lineages (Figure S2A), we identified a number of geneated probes are shown in gray type. The number of probes that are
diagrams.
r matrix proteins and oxidoreductase activity, that were enriched
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Figure 3. Genes Annotated as Transcription Factor Activity Are Immediately Enriched Upon Differentiation
(A) Percentage of probes annotated as TF activity during differentiation into osteoblasts and adipocytes of the total differential expressed
probes.
(legend continued on next page)
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ontology terms that are only enriched during adipogenic
differentiation in phase III (Figures 2B and 2E) and not dur-
ing osteoblast differentiation. The unique regulation of
these gene categories (e.g., monocarboxylic acid binding
[GO: 0033293] and oxidation reduction [GO: 0055114])
suggest changes in metabolic activity in the adipogenic
lineage that do not occur during osteoblast differentiation.
Osteoblast differentiated MSCs are defined in part by the
production of ECM proteins. Indeed, the number of genes
enriched in phase II of osteogenic differentiation is related
to cell adhesion (GO: 0007155), the ECM (GO: 0031012),
and proteinaceous ECM (GO:0005578) (Figures 2E and
S2A). Interestingly, genes with the same GO terms are
also significantly enriched during adipogenic differentia-
tion but at a later stage (phase III). Within 12 hr of differen-
tiation, the expression data show that 23 of 51 and 22 of
50 modulated ECM genes are either osteoblast or adipo-
cyte related, respectively (Figures 2D and 2E). Taken
together, gene ontology analysis establishes that pheno-
type acquisition is initiated in phase I and continues into
phases II and III.
Differential Expression of Transcription Regulators
within 3 hr after Induction of Differentiation in
Phase I
The main class of genes that is activated during phase I
in both osteogenic and adipogenic differentiation is
associated with regulation of transcription (Figure 3A).
This interpretation is based on significant enrichment
of functional categories such as homeobox TFs (IPR:
001356), basic-leucine zipper TFs (IPR: 004827), TF activity
(GO: 0003700), DNA binding (GO: 0003677), as well as
positive and negative regulation of transcription (GO:
0045941 and GO: 0016481) (Figure 2B and Table S1).
Within 1 hr, more than 20% (osteoblast) and 30% (adipo-
cyte) of the regulated genes are related to TF activity (GO:
0003700) and decrease below 10% in both lineages after
6 hr (Figure 3A). Hence, changes in mesenchymal pheno-
types upon induction of differentiation appear to be medi-
ated by rapid changes in the expression of TFs, which can
function as inducers of secondary responses to sustain
either osteogenic or adipogenic phenotype commitment.(B) Venn diagram of all probes annotated as TF activity (GO: 00037
adipocyte and osteoblast differentiation.
(C) Hierarchical clustering of 133 probes of the gene expression stud
green, downregulated relative to undifferentiated cells; yellow, signi
ation; blue, significant differentially expressed within 3 hr of adipoc
(D) GeneMania network analyses of the 77 (88 probes) TFs that were
yellow edges illustrate consolidated pathways and protein domains
osteoblast TFs are marked in red; and green nodes depict the TFs tha
(E) GeneMania network analyses of the 95 (104 probes) TFs that were
colored as in (D). Green nodes are TFs that are specifically regulatedWithin the first phase of osteogenic and adipogenic dif-
ferentiation, there are in total 133 probes (corresponding
to 114 genes) related to transcriptional activity that are
acutely regulated (Figures 3B and 3C). Most of the probe
sets differ in expression in both lineages (i.e., 78%, 69 of
88 upon osteogenic induction; 61%, 69 of 114 upon adipo-
genic induction) (Figures 3B and 3C). A small number of
the regulated transcription-related probes were specifically
regulated in one of the two lineages andmay represent line-
age-specific regulators (i.e., 22%, 19 of 88 in osteogenicme-
dium; 39%, 45 of 114 in adipogenic medium). Transient
upregulation of early-responder TFs in phase I is occasion-
ally followed by a return to basal levels of expression in
phases II and III. This biphasic modulation indicates that
induction of differentiation initiates a primary transcrip-
tional program that may serve to induce a secondary pro-
gram of phenotype-specific genes.
GeneMania network analyses illustrates that the 88 tran-
scription-related probes (80 genes) regulated upon osteo-
genic differentiation are linked to established signaling
pathways such as transforming growth factor b (TGF-b) re-
ceptor signaling, regulation of nuclear Smad2/3 signaling,
and AP1 TF signaling (Figure 3D), perhaps indicating acti-
vation of a TGF-b-Smad2/3-AP1 network. Similar signaling
pathways are evident among the 114 probes (97 genes)
annotated for TFs that are controlled during adipogenic in-
duction (Figure 3E). The TFs regulated in both lineages are
associated with similar pathways, yet these pathways are
linked to TFs with lineage-specific changes in expression.
For example, expression of MEF2A and VDR is modulated
only during osteogenesis and adipogenesis, respectively,
and functionally related to TGF-b receptor signaling (Fig-
ure 3D, arrow). Other TFs regulated during osteogenic dif-
ferentiation of MSCs include five TFs with well-known
roles in skeletal morphogenesis (DLX5, FOXC2, IRX5,
SOX9, and TWIST1) (Figure 3D). Furthermore, there are
many homeobox-domain-containing TFs that are promi-
nently regulated during either osteogenic (12 TFs) or adipo-
genic differentiation (19 TFs) (Figures 3D and 3E). Taken
together, lineage-specific transient stimulation and sup-
pression of early-responder TFs in phase I may represent a
pre-commitment stage that drives activation of the target00) that are differentially expressed within the first 3 hr during
y and annotated as TF activity (depicted in B). Red, upregulated;
ficant differentially expressed within 3 hr of osteoblast differenti-
ytes differentiation.
up- or downregulated during osteoblast differentiation. Gray and
with edges shared, respectively. Blue nodes are pathways; known
t are specifically regulated during osteogenesis. Arrow see text.
up- or downregulated during adipocyte differentiation. Edges are
during adipogenesis.
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genes to establish the specialized mesenchymal pheno-
types that support bone formation or fat metabolism.
Analysis of Upstream Regulators Reveals a
Coordinately Controlled TF-Gene Network
The regulated probes at each individual time point were
selected and used for upstream regulator analyses (URA)
in ingenuity pathway analyses (Figure 4A) to assess if the
modulated genes correlate with TFs that change activity
immediately upon differentiation. URA generated a pattern
for 147 TFs of which the activities are modulated during
osteogenic or adipogenic differentiation (Figure S3A).
Two notable genes activated in both lineages are CDKNA2
and NR3C1. CDKN2A is a major regulator of cellular quies-
cence and senescence, and its activation blocks cell prolif-
eration by ensuring that cell-cycle stimulating regulatory
E2F factors remain sequestered by pRB/p105. NR3C1/GR
encodes a key nuclear receptor that controls gene expres-
sion in response to glucocorticoids (e.g., dexamethasone),
a known stimulant of both osteoblastogenesis and adipo-
genesis that is included as an inducer of differentiation in
our cell-culture experiments. Interestingly, the change in
TF activity of NR3C1 exemplifies that additional post-tran-
scriptional regulations should occur since its expression
level did not change.
URA also identified two other proteins (TP53 and EZH2)
that have direct gene regulatory functions specifically dur-
ing hMSC differentiation. TP53 encodes the tumor sup-
pressor protein p53 that is required for normal osteoblast
differentiation, while EZH2 is a histone methyltransferase
that is known to suppress CDKN2A and control mesen-
chymal differentiation during skeletal development (Duda-
kovic et al., 2015). Beyond CDKN2A and NR3C1, there are
eight other gene regulators (ELF4, FOSB, MYC, NFKBIA,
SMARCB1/BAF45, STAT5A, NR1I3, and THRB/NR1A2)
that are identified byURA in phase I of adipogenic differen-
tiation (Figure S3A) and have direct connections with
adipogenic differentiation based on well-established path-
ways. Collectively, our high-density temporal analysisFigure 4. Ingenuity Upstream Regulator Analyses Identifies Gene
(A) Procedure of the upstream regulator function in Ingenuity (www
(B) Cluster diagram of all TFs that a Z-score of>2 or <2 in either lin
tiation. Next to the activity patterns is the relative expression during d
were not expressed or not present on the array, and therefore no exp
(C) All TFs that were changing activity (blue, Z-score of<2; or red, Z-s
adipocytes (AD), or both (OS and AD).
(D) GeneMania network analyses of the 34 TFs identified. The connecte
osteoblast-specific TFs; green, the adipocyte-specific TFs; gray, the T
(E) Alizarin red staining of hMSC transduced with pLenti6.3-DsRED, pL
osteogenic differentiating conditions.
(F) ALP levels of transduced cells after 7 days osteogenic different
experiment, mean ± SEM; statistical significance using a one-way ANcombined with URA validates the known osteogenic
and/or growth inhibitory functions of four gene regulatory
proteins (i.e., CDKNA2, NR3C1, TP53, and EZH2) during
differentiation of hMSCs.
Many TFs have lineage-independent activation/inhibi-
tion patterns. For example, 71% (phase I), 60% (phase II),
and 59% (phase III) of TFs modulated during osteogenesis
are activated or inhibited during the same phases of adipo-
genesis (Figure S3B). These results show that initiation of
either osteogenic or adipogenic differentiation is mediated
by shared regulatory pathways, and a select number of
critical cell-fate-determining proteins may coordinate acti-
vation of mesenchymal lineage-specific gene expression
programs.
Interestingly, URA predicts that many TFs change their
activity without a change in their expression level. During
osteoblast differentiation, only 14%, 18%, and 23% of the
TFs identified by URA exhibit a change in gene expression
in each of the three different phases, while 30%, 29%, and
33% of these TFs change during adipocyte differentiation
(Figure S3A). Thus, the mRNA-independent activation
and inhibition of TFs predicted by URA suggest phase tran-
sitions during differentiation that may occur via a post-
transcriptional mechanism including translation, protein
modification, and/or subcellular translocation.
Analyses of Early Activated and Inhibited TFs
We subsequently focused our studies on TFs that change ac-
tivity within the first phase (0–3 hr) when cells are postu-
lated to make important lineage decisions (Figures 2 and
4B). Functional annotation illustrated that nearly all iden-
tified TFs are involved in cellular differentiation (30 of 34)
(Figure 4C). More specifically, 7 and 11 of the 34 TFs have
been linked to differentiation of adipocytes and osteo-
blasts, respectively (Figure 4C). Consolidated pathway
analyses illustrated that the identified TFs are involved in
well-known osteoblast and adipocytes signaling pathways
such as GR, AP1, TGF-b, and interferon g (IFN-g) signaling
(Figure 4D) (Augello and De Bari, 2010). Interestingly, theral and Lineage-Specific TF Activity Changes
.ingenuity.com).
eages within the first 3 hr of osteogenic and adipogenic differen-
ifferentiation of the TFs. Expression patterns of genes that are gray
ression data were available.
core of>2) within the first 3 hr of differentiation of osteoblasts (OS),
d edges in gray illustrate the consolidated pathways (blue); red, the
Fs that we identified in both lineages.
enti6.3-IRF2, and non-transduced (NT) and cultured for 21 days in
iation. n = 3 independent experiments with three replicates per
OVA; **p < 0.01, ***p < 0.001; ns, not significant.
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Table 1. Number of Genes Regulated Downstream of the Activated/Inhibited TFs from Phase I
Number of TFs







OS only 4 112 260 438
OS and AD 10 151 272 441
All OS 14 192 408 693
Osteoblast specific 36.6% 52.3% 57.5%
Number of TFs







AD only 20 170 492 647
OS and AD 10 181 431 533
All AD 30 235 706 964
Adipocyte specific 31.8% 55.9% 66.6%downstream analyses of four TFs that changed activity only
during osteogenic differentiation (i.e., TP53, FOSl1, ESR1,
and HOXA9), suggest that they may regulate 36.6% of
the genes that were differential expressed within this first
phase (Table 1). This number increased to 52% and 58%
of the differential expressed genes in phases II and III.
Importantly, this analysis demonstrates that activation or
inhibition of only four TFs within the first 3 hr is linked
to the regulation of more than 50% of the genes at later
stages. Taken together, our analyses validate known regula-
tors of osteoblast differentiation and identify candidates
that may regulate many downstream genes involved in
osteoblast differentiation.
One of the TFs we identified is interferon-regulating fac-
tor 2 (IRF2). This conclusion was based on the direction of
regulation of five IRF2 target genes: IRF1, IL6, CDKN1B,
SOCS1, and PTGS2. To assess the robustness of this conclu-
sion, we studied the expression of these five target genes in
MSCs obtained from four different donors. As shown in
Figure S4, the change in expression was identical in all do-
nors at 3 or 6 hr (Figure S4A and S4B) after the start of oste-
ogenic differentiation. Forced expression of IRF2 in MSCs
resulted in increased ALP activity and ECMmineralization
(Figures 4E and 4F). Thus, IRF2 is functionally rate limiting
for osteogenic lineage commitment and progression of
hMSC differentiation and mineralization.DISCUSSION
The present study provides key insights into mechanistic
events that direct osteoblast and adipocyte differentiation,
which occur before time windows examined by previous
studies (Hung et al., 2004; Kulterer et al., 2007; Ng et al.,
2008; Piek et al., 2010). The high-density temporal dy-956 Stem Cell Reports j Vol. 8 j 947–960 j April 11, 2017namic gene expression profiles we generated permit a
mechanistic description of functional processes that
change during the first hours and days of osteoblast and ad-
ipocytes differentiation. Among the main findings of this
study is the definition of at least three distinct early differ-
entiation phases, each with their own mRNA dynamics,
and the identification of candidates for early regulation
of hMSC differentiation. We used isolated MSCs, which
represent a heterogeneous cell population. However, by us-
ing dexamethasone as inducer of both osteogenic and adi-
pogenic differentiation, we synchronized the clock of the
cells (So et al., 2009), which is coupled to the cell cycle (Feil-
let et al., 2015), and thereby limited cell-cycle heterogene-
ity and explained the identification of cell-cycle-related
genes.
Although we have investigated in detail the differentia-
tionof bonemarrow-derivedMSCs, further in-depth studies
are needed to establish whether MSCs from adipose
tissue or different anatomical locations undergo a similar
cascade of transcriptional events. Although adipose-
derived MSCs could function as a source of hMSCs for
regenerative medicine, previous studies illustrated that
MSCs isolated from different adipose depots respond very
differently with respect to their clonogenic potential,
doubling time, and differentiation (Russo et al., 2014).
Therefore, the gene signature identified here may aid
in the selection of cells from adipose tissue or other
anatomical sites with increased regenerative capacity for
the treatment of skeletal disorders.
Gene expression analyses revealed an increased number
of genes differentially regulated in osteoblasts and adipo-
cytes. Yet, the enriched biological processes and TFs that
change activity are mostly identical between the lineages
within the first 4 days and therefore suggest that the timing
of expression modulation and the specific types of genes
within each functional category differ between the two
lineages.
Based on the number of genes regulated and the unsuper-
vised cluster analyses, we discriminated three different
phases within the first 4 days of differentiation. The third
and last phase (early lineage progression, 48–96 hr) is char-
acterized by a stabilization of the number of differentially
expressed genes and suggests that the differentiating cells
have reached a stable phenotype. The second phase (line-
age acquisition, 6–24 hr) represents a transition phase in
which the two differentiating lineages begin to deviate, as
reflected by many transcriptional changes that are a direct
result of the changes in the first phase. Downstream ana-
lyses of the four TFs that were identified during the first
phase of osteogenic differentiation showed that these are
capable of regulatingmore than 50%of the regulated genes
in the second and third phases.
Within the third phase of osteogenic and adipogenic dif-
ferentiation, most of the genes associated with the cell cy-
cle were downregulated. This illustrates the transition from
proliferation to differentiation and reflects the inverse cor-
relation between these processes as has been described in
various other differentiating cells. The SWI/SNF chromatin
remodeling complex is important for this regulation (Ruij-
tenberg and van den Heuvel, 2016). Moreover, since
RUNX2-dependent skeletal gene expression requires SWI/
SNF, it agrees with the sequential process fromproliferation
to differentiation of hMSCs (Young et al., 2005). Neverthe-
less, we need to investigate whether small molecules that
inhibit proliferation are sufficient for the induction of
differentiation of hMSCs.
In the regulatory model derived from our data, the first
phase (0–3 hr) represents the initiation stage of the differ-
entiation program of hMSCs. This phase is character-
ized by expression changes of many transcription-related
genes that regulate lineage commitment and set the
stage for further differentiation toward a stable pheno-
type. We identified many TFs with homeobox and bZip
domains that were regulated in both lineages. Homeobox
TFs have been extensively studied and are generally
important for their regulatory effects during develop-
ment, as well as MSC differentiation (Stains and Civitelli,
2003). Strikingly, the homeobox TF DLX5 is upregulated
within the first hours of differentiation. Dlx5 is epige-
netically unlocked during DMSO-induced osteogenic
differentiation (Thaler et al., 2012), activates the osteo-
blast TF Runx2 (Lee et al., 2005), and is required for
mesenchymal cell proliferation and differentiation (Sa-
mee et al., 2008). Interestingly, seven homeobox TFs
(e.g., HOXA10, HOXB2, IRX3, SATB2, SIX2, SIX4, and
ZFHX4) are only regulated upon adipocyte differentiation.
Apart from HOXA10, these TFs have not yet been
described to be involved in adipocyte differentiation andhold the potential of early regulators for lineage specificity
and commitment.
Consolidated pathway analyses of the immediately early-
regulated TFs identify Smad2/3-TGF-b and AP1 signaling.
TGF-b and AP1 signaling are also enriched in the URA of
the regulated genes in the first phase. Because most of the
TFs within these pathways are regulated in both differenti-
ating osteoblasts and adipocytes, we hypothesize that the
initiation of hMSC differentiation is similarly activated in
both lineages and that changes in the combination of these
signaling pathways are necessary to exit the immature
multi-potent cell stage (loss of stemness) to allow acquisi-
tion of a specialized mesenchymal phenotype. Indeed, the
dominant PC of expression changes may correspond to
this loss of stemness. The TGF-b family member Activin A
inhibits differentiation and bone formation of committed
osteoblasts (Eijken et al., 2007) by altering the ECMcompo-
sition (Alves et al., 2013). Because most TFs associated with
TGF-b signaling (e.g., ESR1, FOSB, HOXA9, JUNB, MEF2A,
and MYC) appear to be inhibited in our URA and because
the Activin-antagonist follistatin enhances osteoblast
differentiation (Eijken et al., 2007), we hypothesize that
inhibition of TGF-b signaling is essential for early initiation
of osteogenic differentiation of hMSCs.
Our studies also identified IRF2 as a regulator of osteoblas-
togenesis inhMSCs. Irf2 is an antagonist of Irf1 and inhibits
the transcriptional activation by IFN-a and -b (Zhang et al.,
2015), and has a separate function in cell proliferation
(Vaughan et al., 1995). In addition, we found that IFN-g-
pathway-associated TFs (e.g., CEBPb, CREB1, HOXA10,
STAT5A, STAT5B, and STAT6) change activity within the
first phase. Consistent with these findings, IFNs do not
affect induction of osteogenic differentiation in hMSCs,
but they inhibit mineralization when administered after
lineage commitment (2 days after initiating osteogenic dif-
ferentiation) (Woeckel et al., 2012) or to pre-committed
immortalized human fetal osteoblasts. Taken together,
these findings indicate that regulation of IFN signaling is
important for the osteogenic differentiation of hMSCs.
In conclusion, our data show that a stable osteoblast or
adipocyte phenotype is established within the first 2 days
upon induction of lineage commitment in hMSC. Three
distinct early phases with characteristic cellular responses
and differentially expressed TFs are evident during both
adipogenic and osteogenic differentiation. We observed
that adipogenic differentiation of MSCs derived from
young healthy individuals required a higher number of
genes to change in expression than osteogenic differentia-
tion. This observation together with the known shift in bal-
ance between adipocyte and osteoblast differentiationwith
aging (Li et al., 2016) motivates further studies to investi-
gate the extent of transcriptional changes as a function
of age or gender. Interestingly, changes in TF activity thatStem Cell Reports j Vol. 8 j 947–960 j April 11, 2017 957
occur within the first 3 hr may control regulation of subse-
quent later phases of mesenchymal differentiation. Up-
stream regulator analyses identified TFs in both canonical
and less explored signaling pathways. The latter finding
opens up possibilities for studies on small molecules that
target early regulators to efficiently induce osteoblast and
adipocytes differentiation, as part of a bone anabolic strat-
egy for osteoporosis.EXPERIMENTAL PROCEDURES
Cell Culture
Bonemarrow-derived hMSCs andNHOst fromhealthy individuals
were obtained from Lonza and differentiated as previously
described (Bruedigam et al., 2011). The donor characteristics
of the different hMSC batches were as follows: donor 1, 19 years,
male, ethnicity unknown (microarray study); donor 2, 22
years, male, white; donor 3, 20 years, male, black; donor 4, 33
years, male, black. Briefly, hMSC and NHOst at passage 2 were
expanded in Mesenchymal Stem Cell GrowthMedia or Osteoblast
Basal Growth Media (Lonza, Switzerland), respectively, and and
5 3 103 vital cells/cm2 (hMSC) or 1 3 104 vital cells/cm2 (NHOst)
were seeded in 12-well cell-culture plates in aMEM (Life Technolo-
gies, including 50 mg/mL ascorbic acid) supplemented with 10%
heat-inactivated fetal calf serum (Invitrogen), 20 mM HEPES
(Sigma), 1.8 mM CaCl2 (Sigma), and adjusted to pH 7.5. Two
days after seeding, cells were differentiated into adipocytes using
aMEM supplemented with 100 nM dexamethasone (Sigma),
60 mM 3-isobutyl-1-methylxanthine (Sigma) and 500 mM indo-
methacin (Sigma), or differentiated into osteoblasts using aMEM
supplemented with 100 nM dexamethasone (Sigma) and 10 mM
b-glycerophosphate (Sigma) and cultured at 37C and 5% CO2 in
a humidified atmosphere. Differentiation media were replaced
every 3–4 days and not during the first 96 hr of the experiment.DNA, Protein, Alkaline Phosphatase Activity, and
Mineralization Assays
DNA, protein, ALP activity, and calcium measurements were per-
formed as previously described (Bruedigam et al., 2011).RNA Isolation
For each time point, nine individual wells withMSCswere induced
to differentiate into the osteogenic as well as the adipogenic line-
age. To obtain enough RNA for the gene expression profiling ana-
lyses, we pooled three individual cultures in TRIzol (Life Technol-
ogies), resulting in a total of three experimental samples per time
point (11 time points) per lineage (osteogenic or adipogenic) to
be used for gene expression profiling analyses (66 samples in total).
RNA was isolated as previously described (Bruedigam et al., 2011).
The quality of isolated RNA was assessed on a 2100 Bioanalyzer
(Agilent Technologies).Illumina Gene Chip-Based Gene Expression Profiling
Illumina HumanHT-12 v3 BeadChip (Illumina) human whole-
genome expression arrays were used. RNA from three biological rep-958 Stem Cell Reports j Vol. 8 j 947–960 j April 11, 2017licates for each condition and time point were analyzed. Total RNA
(100 ng) of each sample was amplified using an Illumina TotalPrep
RNA Amplification Kit (Ambion). cRNA (750 ng) was hybridized
using the standard Illumina protocol and scanned on an iScan.
Microarray Analysis
Raw data were background subtracted using Illumina
GenomeStudio (V2010.1, Illumina), and further processed using
the Bioconductor R2.10.1 lumi-package (Du et al., 2008). Data
were transformedusingvariance stabilizationandquantilenormal-
ized. Probes that were present at least once in the experiments
(detection p value <0.01) were considered to be expressed (15,795
probes) and further analyzed. Differential expressed probes, q <
0.001, were calculated using the Bioconductor package limma
(Smyth, 2004).
Enriched Functional Categories, Ingenuity Pathway
Analysis, and GeneMania Network Generation
For each time point, we selected the significant regulated probes
(q value <0.001 versus undifferentiated hMSCs), and enriched
functional categories were calculated using DAVID v6.7 (http://
david.abcc.ncifcrf.gov/ (Huang et al., 2009)). The 100 most signifi-
cant functional categories (based on p value) per phase (0–3 hr,
6–24 hr, 48–96 hr) and lineage (adipogenic, osteogenic) were
selected. The enrichment p values for each time point and treat-
mentwere added to the functional categories (in total 285, seeTable
S1). The p values werelog10 transformed and visualized in a clus-
ter tree using JavaTreeView. Consolidated pathway analyses were
performed with GeneMania (www.genemania.org). The URA for
each time point was performed using ingenuity pathway analysis
(www.ingenuity.com). TFs with a Z score below 2 or above 2
were considered inhibited or activated. For the downstream ana-
lyses depicted inTable 1,we counted thenumber of genes inphases
II and III that canbe regulatedby the TFs in thefirst phase. The clus-
ter analyses of the Z scores were visualized using JavaTreeView.
Generation of Overexpression Constructs
Overexpression constructs were generated using Gateway cloning
(Invitrogen). Constructs containing the gene of interest (pCMV-
SPORT6-IRF2: 3920890) were ordered from Open Biosystems.
PCR products without a stop codon were generated from these
constructs (primers: IRF2-for, caccatgccggtggaaaggatgc; IRF2-rev,
acagctcttgacgcgggcctg) and ligated into pENTR-topo (Invitrogen)
using the supplier’s protocol. The generated Entry clone was
sequenced and the insert was transferred into pLenti6.3/v5-DEST
(Invitrogen) destination vector using an LR-gateway reaction
according to the supplier’s protocol. Virus production was
carried out as previously described using Virapower lentiviral
packaging constructs (Drabek et al., 2011). Subsequently, virus-
containing media were concentrated using ultracentrifugation
at 22,800 rpm in a SW32ti rotor (Beckman Coulter) at 4C.
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